Dataset opportunity
Endiatx — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Endiatx, usable for Diagnostic AI and Computer Vision.
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market = US$ 1.70 billion in 2024, projected to reach US$ 16.88 billion by 2034, growing at a CAGR of 25.8% (2025-2034).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-05
J&J, Medtronic back CereVasc’s $85M funding round
medtechdive.com ↗ - 📰press2026-06-05
Olympus’ Keith Boettiger on robotic GI surgery push
medtechdive.com ↗ - 📰press2026-06-05
Dexcom buys Nutrisense; Insulet rolls out patch pump update
medtechdive.com ↗ - 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
More Americans own wearables, connected health devices: survey
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Endiatx possesses a valuable Medical Imaging Dataset (specifically Image modality) derived from diagnostic procedures, significantly enhanced by associated IoT data and comprehensive medical records, contributing to a robust data volume. This rich dataset is ideally suited for training and validating advanced Diagnostic AI models, enabling improved accuracy and efficiency in medical diagnosis.
The AI in Medical Imaging market demonstrates substantial business value, with an estimated market size of US$ 1.70 billion in 2024, projected to grow to US$ 16.88 billion by 2034, at a compelling CAGR of 25.8%. Despite inherent access complexity stemming from FDA approval requirements, stringent patient privacy concerns (HIPAA/GDPR equivalent), the necessity for explicit patient consent for secondary use, and limited commercial data volume due to ongoing clinical trials, this high-quality medical data remains highly sought after by Diagnostic AI buyers. Its rarity and potential to revolutionize diagnostics make it a critical asset in a rapidly expanding market. ⚠ Diligence (valuable data, access to negotiate): FDA approval required for commercial use of the device, impacting data generation volume and accessibility.; Patient privacy (HIPAA/GDPR equivalent) concerns due to highly sensitive medical imaging data.; Data is generated during diagnostic procedures, likely requiring explicit patient consent for any secondary use.; Currently in clinical trials, so the volume of commercially generated data is limited until full launch. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
Endiatx holds a proprietary and exceptionally rare dataset of real-time, high-resolution video captured directly from inside the stomach by its innovative PillBot robotic capsule. This unique medical imaging data is precisely what diagnostic AI and medical-imaging companies need to develop groundbreaking solutions for gastrointestinal analysis. It represents a critical asset for advancing AI in a market projected to grow from US$ 1.70 billion in 2024 to US$ 16.88 billion by 2034, offering a significant competitive edge now.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
The AI in medical imaging market, which relies heavily on these datasets, was valued at USD 1.38 billion in 2022 and is projected to grow at a CAGR of over 30.5% from 2023 to 2032, indicating extremely high and increasing buyer demand.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ good target — Endiatx is a medical robotics company developing a diagnostic device (PillBot) that generates valuable, niche, proprietary medical imaging data as a by-product of its core operational business, making it a good target for a data marketplace, although there are stated intentions to offer data service Issues: Endiatx has stated an intention to offer "data services" as part of its ecosystem, which could potentially evolve into a core business of selling data or intell; Employee coun
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms Endiatx generates real-time, high-resolution video from its PillBot, providing unique in-vivo imaging data essential for training advanced diagnostic AI models for gastrointestinal conditions.
IoT / sensor data
This indicates Endiatx possesses multimodal operational data from the PillBot, including time-series data on its movement and remote control, which is invaluable for understanding device performance and contextualizing the visual data for AI development.
Data-volume signal
The ongoing clinical trials for PillBot 1.0 and development of PillBot 2.0 confirm a continuous and expanding pipeline of multimodal data generation, ensuring a growing volume of high-quality, real-world data for long-term AI model refinement.
Coverage
Scanned sources
Deliverable
Premium dataset report
Endiatx Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = US$ 1.70 billion in 2024, projected to reach US$ 16.88 billion by 2034, growing at a CAGR of 25.8% (2025-2034).. Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.